Intelligent Optimization of Personalized Drug Combination Strategies Using Multimodal Medical Imaging and Real-Time Decision-Making Algorithms

Authors

  • Kerri Esparza Department of Computer Science, University of North Texas, Denton, TX, USA.
  • Timoteo Fajardo Department of Computer Science and Engineering, University at Buffalo, Buffalo, NY, USA.

Keywords:

personalized drug combination optimization; multimodal medical imaging; constrained decision-making; Bayesian uncertainty quantification; safe reinforcement learning; clinical decision support

Abstract

Personalized drug combination selection requires reconciling heterogeneous imaging evidence, longitudinal clinical history, treatment exposure, and uncertain response and toxicity outcomes within a constrained decision process. Multimodal medical imaging can characterize tumor burden, spatial heterogeneity, organ reserve, and early response, but imaging-derived phenotypes are rarely integrated into a coherent combinatorial optimization framework that also enforces safety constraints and supports sequential adaptation. This manuscript develops a methodological framework for intelligent optimization of personalized drug combinations using multimodal imaging and real-time decision algorithms. The central contribution is a constrained, uncertainty-aware decision architecture that represents each patient as a partially observed state, fuses imaging and non-imaging evidence into a latent response phenotype, estimates efficacy and toxicity surrogates under counterfactual treatment assumptions, and selects combinations through a constrained utility objective with explicit safety gating. The framework combines multimodal representation learning, probabilistic response and toxicity modeling, combinatorial optimization over doses and schedules, belief-state updating, model-predictive or policy-based sequential decision-making, and calibrated deferral when evidence is insufficient. It specifies the inputs, model outputs, objective functions, constraints, uncertainty logic, and evaluation criteria needed to move from imaging biomarkers to defensible combination recommendations. Technical discussion addresses confounding by indication, missing modalities, distribution shift, feedback loops, safety assurance, and human oversight. The framework provides a coherent basis for prospective validation and for the design of clinical decision support that treats imaging evidence as a dynamic state variable rather than a static predictor.

References

1. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56. https://doi.org/10.1038/s41591-018-0300-7

2. Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. New England Journal of Medicine, 380(14), 1347–1358. https://doi.org/10.1056/NEJMra1814259

3. Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2017). Dermatologist-level classification of skin cancer with deep neural networks. Nature, 542(7639), 115–118. https://doi.org/10.1038/nature21056

4. Shen, D., Wu, G., & Suk, H.-I. (2017). Deep learning in medical image analysis. Annual Review of Biomedical Engineering, 19, 221–248. https://doi.org/10.1146/annurev-bioeng-071516-044442

5. Al-Lazikani, B., Banerji, U., & Workman, P. (2012). Combinatorial drug therapy for cancer in the post-genomic era. Nature Biotechnology, 30(7), 679–692. https://doi.org/10.1038/nbt.2284

6. Jia, J., Zhu, F., Ma, X., Cao, Z., Cao, Y., Li, Y., Li, Y., & Chen, K. (2009). Mechanisms of drug combinations: Interaction and network perspectives. Nature Reviews Drug Discovery, 8(2), 111–128. https://doi.org/10.1038/nrd2683

7. Preuer, K., Lewis, R. P. I., Hochreiter, S., Tsamardinos, I., & Klambauer, G. (2018). DeepSynergy: Predicting anti-cancer drug synergy with deep learning. Bioinformatics, 34(9), 1538–1546. https://doi.org/10.1093/bioinformatics/btx806

8. Shahriari, B., Swersky, K., Wang, Z., Adams, R. P., & de Freitas, N. (2016). Taking the human out of the loop: A review of Bayesian optimization. Proceedings of the IEEE, 104(1), 148–175. https://doi.org/10.1109/JPROC.2015.2494218

9. Luo, D., Gattas, J. M., & Tan, P. S. S. (2020, July). Real-time defect recognition and optimized decision making for structural timber jointing. In The International Conference on Computational Design and Robotic Fabrication (pp. 36-45). Singapore: Springer Singapore.

10. Ghassemi, M., Oakden-Rayner, L., & Beam, A. L. (2021). The false hope of current approaches to explainable artificial intelligence in health care. The Lancet Digital Health, 3(11), e745–e750. https://doi.org/10.1016/S2589-7500(21)00208-9

11. Begoli, E., Bhattacharya, T., & Kusnezov, D. (2019). The need for uncertainty quantification in machine-assisted medical decision making. Nature Machine Intelligence, 1(1), 20–23. https://doi.org/10.1038/s42256-018-0004-1

12. Schulam, P., & Saria, S. (2017). Reliable decision support using counterfactual models. In Advances in Neural Information Processing Systems (Vol. 30, pp. 1697–1708). Curran Associates.

13. Gottesman, O., Johansson, F., Komorowski, M., Faisal, A., Sontag, D., Doshi-Velez, F., & Celi, L. A. (2019). Guidelines for reinforcement learning in healthcare. Nature Medicine, 25(1), 16–18. https://doi.org/10.1038/s41591-018-0310-5

14. Sutton, R. S., & Barto, A. G. (2018). Reinforcement learning: An introduction (2nd ed.). MIT Press.

15. Jospin, L. V., Laga, H., Boussaid, F., Buntine, W., & Bennamoun, M. (2022). Hands-on Bayesian neural networks—A tutorial for deep learning users. IEEE Computational Intelligence Magazine, 17(2), 29–48. https://doi.org/10.1109/MCI.2022.3155327

16. Kaelbling, L. P., Littman, M. L., & Cassandra, A. R. (1998). Planning and acting in partially observable stochastic domains. Artificial Intelligence, 101(1–2), 99–134. https://doi.org/10.1016/S0004-3702(98)00023-X

17. Garcia, J., & Fernández, F. (2015). A comprehensive survey on safe reinforcement learning. Journal of Machine Learning Research, 16(1), 1437–1480.

18. Altman, D. G., & Royston, P. (2000). What do we mean by validating a prognostic model? Statistics in Medicine, 19(4), 453–473. https://doi.org/10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5

19. Collins, G. S., Reitsma, J. B., Altman, D. G., & Moons, K. G. M. (2015). Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement. Annals of Internal Medicine, 162(1), 55–63. https://doi.org/10.7326/M14-0697

20. Amodei, D., Olah, C., Steinhardt, J., Christiano, P., Schulman, J., & Mané, D. (2016). Concrete problems in AI safety. arXiv. https://arxiv.org/abs/1606.06565

Downloads

Published

2026-10-21

How to Cite

Kerri Esparza, & Timoteo Fajardo. (2026). Intelligent Optimization of Personalized Drug Combination Strategies Using Multimodal Medical Imaging and Real-Time Decision-Making Algorithms. International Journal of Clinical and Translational Medicine, 2(2). Retrieved from https://ijctmed.org/index.php/home/article/view/241